Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2024-11-10 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
第三届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the third board of directors of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, agenda items, and voting results. The content focuses on board meeting decisions, including approval of a dividend distribution proposal and the scheduling of a shareholders' meeting. There is no detailed financial report or comprehensive analysis, but rather a summary of board decisions and procedural compliance. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length is short (1227 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2024-11-10 Chinese
第三届监事会第五次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolution passed at the fifth meeting of the third Supervisory Board of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and the approval of a proposal regarding the 2024 third quarter dividend distribution plan. The document states the dividend proposal will be submitted to the shareholders' meeting for approval and references a related announcement (2024-089) on the stock exchange information disclosure platform. The document is short (880 characters) and primarily serves as an official meeting resolution announcement rather than a full financial report or detailed dividend notice. It does not contain actual financial statements or detailed dividend payment instructions but rather the meeting's decision and voting results. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially announces the voting results of a corporate meeting resolution related to dividend distribution.
2024-11-10 Chinese
2024年第三季度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the company's 2024 third quarter profit distribution plan (权益分派预案公告). It includes information on the proposed dividend payout, legal and procedural details about profit distribution, board and supervisory committee approvals, and references to the upcoming shareholder meeting for final approval. The document does not contain actual financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related governance. The document length is 4565 characters, which is relatively short and consistent with an announcement rather than a full report. It explicitly states it is a "权益分派预案公告" (profit distribution plan announcement). Therefore, this document fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2024-11-10 Chinese
关于召开2024年第二次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2024 second extraordinary general meeting of shareholders (临时股东大会) for Jiangxi New Ganjiang Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), eligibility, agenda items (such as the 2024 Q3 dividend distribution proposal), registration methods, and other procedural information. There is no actual financial data or results presented, nor is this a transcript or report of the meeting itself. The document is an announcement informing shareholders about the upcoming meeting and how to participate. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this is a notice of the meeting itself and voting arrangements rather than solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is 2228 characters, which is typical for such notices. Hence, the classification is PSI with high confidence.
2024-11-10 Chinese
关于新增2024年度日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the addition of daily related-party transactions for the fiscal year 2024 by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the expected transaction amounts, related parties, board and supervisory approvals, pricing policies, and the impact on the company. It is not a full financial report, audit report, or earnings release. It is a regulatory announcement about related-party transactions, including board meeting resolutions and compliance with listing rules. The document length is about 3007 characters, which is relatively short and focused on a specific corporate disclosure. This fits best under Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories like MANG (management changes) or CAP (capital updates).
2024-11-05 Chinese
第三届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board (监事会) of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the convening, attendance, and voting results of the third Supervisory Board's fourth meeting. The content focuses on the approval of a proposal regarding new related-party transactions for 2024. There is no financial data, no detailed report, and no indication of an annual or interim report. The document is a formal announcement of a board meeting resolution, not a full management or board report. It is not a proxy solicitation or voting result announcement for shareholders, but a supervisory board meeting resolution. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-11-05 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.